Elicio Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Elicio Therapeutics, Inc. (ELTX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-51.90-35.20-28.21-26.40-80.11
Depreciation & Amortization1.181.171.070.250.63
Stock Based Compensation1.451.180.580.620.30
Change in Working Capital3.96-0.060.690.8725.77
Change in Accounts Payable-3.330.021.130.031.12
Change in Other Working Capital7.29-0.083.600.67-2.66
Other Operating Activities8.240.103.340.6720.96
Net Cash from Operating Activities-37.07-32.69-22.18-23.94-22.89
Investing Activities
Capital Expenditures-0.09-0.070.65-0.53-0.04
Acquisitions0.0024.000.000.000.00
Other Investing Activities0.000.000.000.000.00
Net Cash from Investing Activities-0.08-0.03-0.65-0.53-0.04
Financing Activities
Debt Repayment19.730.00-0.06-0.440.00
Common Stock Issued5.647.130.080.1020.05
Common Stock Repurchased0.00-0.150.000.000.00
Other Financing Activities16.9621.640.000.21-0.04
Net Cash from Financing Activities42.3238.6121.2019.3952.41
Summary
Effect of Forex Changes on Cash0.020.000.180.00-0.44
Net Change in Cash5.195.89-1.63-5.0729.48
Cash at Beginning of Period14.308.4110.0515.125.57
Cash at End of Period19.4914.308.4110.0434.61
Free Cash Flow-37.16-32.76-22.83-24.46-22.93
Supplemental Disclosures
Interest Paid0.000.000.000.010.00